Novo Nordisk A/s Class B · OMXCOP:NOVO_B
Novo Nordisk A/s Class B — Investor Day (September 2026)
14 slides from Novo Nordisk A/s Class B's investor day presentation, Sep 21, 2026
Slide 1: R&D strategy
R&D strategy Martin Holst Lange CMD26 CSO, EVP, Research & Development Mishal Patel GVP, AI & Digital Innovation Capital Markets Day 21 September
Slide 2: Forward-looking statements
2 R&D strategy Forward-looking statements Novo Nordisk’s statutory Annual Report 2025, Form 20-F, any quarterly financial reports, the materials displayed and other information provided (orally or in writing) at this Capital Markes Day as well as written information released, shown, or oral statemen
Slide 3: The research & development 2030 ambition is to expand, develop and secure approval of a leading portfolio at speed
3 R&D strategy The research & development 2030 ambition is to expand, develop and secure approval of a leading portfolio at speed 2026-2030 research & development ambition Consistently deliver high- Maintain therapy area Focus pipeline towards Accelerate development quality clinical assets leadershi
Slide 4: Novo has a broad and deep pipeline designed to meet 2030 ambitions and fuel future growth
4 R&D strategy Novo has a broad and deep pipeline designed to meet 2030 ambitions and fuel future growth Novo strategy Planned FHD1 Phase 1 Phase 2 Phase 3 Submitted NNC0497-0040 UBT251 Zenagamtide CagriSema Strengthen and expand 2 assets Type 2 diabetes Type 1 diabetes PPIA Type 2 diabetes Type 2 d
Slide 5: Research & development innovation approach applies balanced biology risk to an emerging landscape of patient needs
5 R&D strategy Research & development innovation approach applies balanced biology risk to an emerging landscape of patient needs Balancing established and innovative biologies to drive value Solving for patient needs across multiple parameters Efficacy Foundational biology Transformational biology
Slide 6: Novo is applying an updated modality approach to address patient needs
6 R&D strategy Novo is applying an updated modality approach to address patient needs Prioritising modalities to build upon current leadership while making strategic Solving for patient needs across multiple investments in emerging areas parameters Blood & Cardio- Liver Strategy Modality Diabetes Ob
Slide 7: AI is leveraged to improve speed, success and productivity across the research & development value chain
7 R&D strategy AI is leveraged to improve speed, success and productivity across the research & development value chain Select achievements in 2026 2026 – 2030 R&D ambition Increasing quality of Biology improved target hit rate by prioritising decisions >3x genes found in virtual assays Evaluating m
Slide 8: AI-enabled active learning accelerated the design of a once-monthly amylin with faster and fewer cycles
8 R&D strategy AI-enabled active learning accelerated the design of a once- monthly amylin with faster and fewer cycles Human and machine learning design was applied to optimise Proof of concept for a scalable, AI-enabled drug design model once-monthly amylin analogues ILLUSTRATIVE ILLUSTRATIVE Roun
Slide 9: First human dose studies have accelerated in 2026, including multiple novel obesity assets with potential for differentiation
9 R&D strategy First human dose studies have accelerated in 2026, including multiple novel obesity assets with potential for differentiation 2026 on track to have more First human doses planned in 2026, with potential for submission by the end of the decade FHDs vs 2018-2025 average First human dose
Slide 10: Oral ACSL5i combines a novel mechanism of action with the potential for convenient, well-tolerated oral weight management
10 R&D strategy Oral ACSL5i combines a novel mechanism of action with the potential for convenient, well-tolerated oral weight management Acyl-CoA synthetase 5 is a non-incretin Oral ACSL5i reduces bodyweight in DIO Profile potential of oral ACSL5i is pathway mice with additive effects to semaglutid
Slide 11: The patient reach of our core modalities is expanding with innovative oral delivery technology
11 R&D strategy The patient reach of our core modalities is expanding with innovative oral delivery technology SNAC technology has established Novo as Novo has an advanced oral pipeline and is building to compete in small molecules a leader in oral biologics SNAC generation optimisation1 Preclinical
Slide 12: Explorative consumer Rx indications are being pursued based on scientific and commercial synergies
12 R&D strategy Explorative consumer Rx indications are being pursued based on scientific and commercial synergies Consumer Rx indications are explored from a premise of scientific evidence and degree of consumer-like decision-making Consumer Rx joins patient needs with Select therapy areas under ex
Slide 13: Novo will continue to expand and strengthen the pipeline via external innovation
13 R&D strategy Novo will continue to expand and strengthen the pipeline via external innovation Select examples and milestones Pursuing value-creating bolt-on acquisitions supported by the science SNAC technology Oral biologics • Wegovy® pill and Ozempic® pill approvals • Oral zenagamtide phase 3 i
Slide 14: R&D set up to deliver >5 multi blockbusters by 2030, with anticipated annual approvals
14 R&D strategy 1 2 3 R&D set up to deliver >5 multi Rapidly expanding our pipeline value by, Significant changes in our R&D set-up blockbusters by 2030, with anticipated significant step up in FHDs, full range of and AI capabilities to deliver at quality annual approvals across therapy areas modali